Vaccine vaccine_老虎社区_美港股上老虎

MP88
2021-08-04

Vaccine vaccine

Why Shares of Moderna Are Up Today<blockquote>为什么Moderna的股价今天上涨</blockquote>

A regulatory action is giving investors a glimpse of its business beyond the pandemic. What happened

Why Shares of Moderna Are Up Today<blockquote>为什么Moderna的股价今天上涨</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":807248031,"tweetId":"807248031","gmtCreate":1628040781123,"gmtModify":1633754141323,"author":{"id":3582798202671514,"idStr":"3582798202671514","authorId":3582798202671514,"authorIdStr":"3582798202671514","name":"MP88","avatar":"https://static.tigerbbs.com/98ab4cdb5a6f628d50eef8b5db5303aa","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Vaccine vaccine</p></body></html>","htmlText":"<html><head></head><body><p>Vaccine vaccine</p></body></html>","text":"Vaccine vaccine","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/807248031","repostId":1199496640,"repostType":4,"repost":{"id":"1199496640","kind":"news","pubTimestamp":1628039112,"share":"https://www.laohu8.com/m/news/1199496640?lang=zh_CN&edition=full","pubTime":"2021-08-04 09:05","market":"us","language":"en","title":"Why Shares of Moderna Are Up Today<blockquote>为什么Moderna的股价今天上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199496640","media":"The Motley Fool","summary":"A regulatory action is giving investors a glimpse of its business beyond the pandemic.\nWhat happened","content":"<p><i>A regulatory action is giving investors a glimpse of its business beyond the pandemic.</i></p><p><blockquote><i>监管行动让投资者得以一窥其在疫情之外的业务。</i></blockquote></p><p> <h3><b>What happened</b></h3> Shares of&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> are up 9% as of 2:45 p.m. EDT today, after the Food and Drug Administration (FDA) granted Fast Track designation for mRNA-1345, the company's vaccine candidate for respiratory syncytial virus (RSV). In April, the company provided data showing an 11-fold and 20-fold increase in neutralizing antibodies for RSV-B and RSV-A, respectively, compared with its previous vaccine candidate.</p><p><blockquote><h3><b>发生了什么</b></h3>本公司之股份<a href=\"https://laohu8.com/S/MRNA\">莫德纳公司。</a>截至下午2:45上涨9%美国东部时间今天，美国食品和药物管理局(FDA)授予该公司呼吸道合胞病毒(RSV)候选疫苗mRNA-1345快速通道指定。今年4月，该公司提供的数据显示，与之前的候选疫苗相比，RSV-B和RSV-A的中和抗体分别增加了11倍和20倍。</blockquote></p><p> <h3><b>So what</b></h3> RSV typically produces cold-like symptoms that last for a week or two. However, it does lead to about 58,000 hospitalizations in young children and 177,000 in older adults every year in the U.S. The agency's designation only applies to people over 60 years old.</p><p><blockquote><h3><b>那又怎样</b></h3>RSV通常会产生持续一两周的感冒样症状。然而，在美国，它每年确实导致约58,000名幼儿和177,000名老年人住院。该机构的指定仅适用于60岁以上的人。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b8a6a5fe1572f41187b8240e772c0216\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p> There is currently no approved vaccine for RSV. The Fast Track designation is a way for the FDA to expedite development of drugs that treat a currently unmet need. The process has lost some of its meaning in recent years. As an example, 73% of new drugs received the designation in 2018.</p><p><blockquote>目前还没有批准的RSV疫苗。快速通道指定是FDA加快开发治疗目前未满足需求的药物的一种方式。近年来，这一进程已经失去了一些意义。例如，2018年有73%的新药获得了认定。</blockquote></p><p> <h3><b>Now what</b></h3> If Moderna can commercialize the drug, it won't have to share the rewards. It owns 100% of the asset. Although the market is estimated at less than $1 billion, the impact could be more substantial. It plans to create a seasonal respiratory vaccine to protect against RSV, COVID-19, and influenza. Insurers would be more likely to push that drug, as combining one shot for multiple protections is likely to increase compliance with recommended inoculations.</p><p><blockquote><h3><b>现在怎么办</b></h3>如果Moderna能够将该药物商业化，它就不必分享回报。它拥有该资产的100%。尽管该市场估计不到10亿美元，但影响可能会更大。它计划开发一种季节性呼吸道疫苗来预防呼吸道合胞病毒、新冠肺炎病毒和流感。保险公司更有可能推广这种药物，因为结合一次注射进行多种保护可能会提高对推荐接种的依从性。</blockquote></p><p> In the short term, the $19.2 billion Moderna expects from its COVID-19 vaccine far outweighs any impact from the RSV vaccine. However, it's a positive signal that the company will be able to leverage its mRNA platform andcommercialize drugsbeyond the pandemic.</p><p><blockquote>短期内，Moderna预计其COVID-19疫苗带来的192亿美元收入远远超过RSV疫苗的任何影响。然而，这是一个积极的信号，表明该公司将能够利用其mRNA平台并在大流行之外将药物商业化。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Shares of Moderna Are Up Today<blockquote>为什么Moderna的股价今天上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Shares of Moderna Are Up Today<blockquote>为什么Moderna的股价今天上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Motley Fool</strong><span class=\"h-time small\">2021-08-04 09:05</span>\n</p>\n</h4>\n</header>\n<article>\n<p><i>A regulatory action is giving investors a glimpse of its business beyond the pandemic.</i></p><p><blockquote><i>监管行动让投资者得以一窥其在疫情之外的业务。</i></blockquote></p><p> <h3><b>What happened</b></h3> Shares of&nbsp;<a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a> are up 9% as of 2:45 p.m. EDT today, after the Food and Drug Administration (FDA) granted Fast Track designation for mRNA-1345, the company's vaccine candidate for respiratory syncytial virus (RSV). In April, the company provided data showing an 11-fold and 20-fold increase in neutralizing antibodies for RSV-B and RSV-A, respectively, compared with its previous vaccine candidate.</p><p><blockquote><h3><b>发生了什么</b></h3>本公司之股份<a href=\"https://laohu8.com/S/MRNA\">莫德纳公司。</a>截至下午2:45上涨9%美国东部时间今天，美国食品和药物管理局(FDA)授予该公司呼吸道合胞病毒(RSV)候选疫苗mRNA-1345快速通道指定。今年4月，该公司提供的数据显示，与之前的候选疫苗相比，RSV-B和RSV-A的中和抗体分别增加了11倍和20倍。</blockquote></p><p> <h3><b>So what</b></h3> RSV typically produces cold-like symptoms that last for a week or two. However, it does lead to about 58,000 hospitalizations in young children and 177,000 in older adults every year in the U.S. The agency's designation only applies to people over 60 years old.</p><p><blockquote><h3><b>那又怎样</b></h3>RSV通常会产生持续一两周的感冒样症状。然而，在美国，它每年确实导致约58,000名幼儿和177,000名老年人住院。该机构的指定仅适用于60岁以上的人。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b8a6a5fe1572f41187b8240e772c0216\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">IMAGE SOURCE: GETTY IMAGES.</p><p><blockquote>图片来源：盖蒂图片社。</blockquote></p><p> There is currently no approved vaccine for RSV. The Fast Track designation is a way for the FDA to expedite development of drugs that treat a currently unmet need. The process has lost some of its meaning in recent years. As an example, 73% of new drugs received the designation in 2018.</p><p><blockquote>目前还没有批准的RSV疫苗。快速通道指定是FDA加快开发治疗目前未满足需求的药物的一种方式。近年来，这一进程已经失去了一些意义。例如，2018年有73%的新药获得了认定。</blockquote></p><p> <h3><b>Now what</b></h3> If Moderna can commercialize the drug, it won't have to share the rewards. It owns 100% of the asset. Although the market is estimated at less than $1 billion, the impact could be more substantial. It plans to create a seasonal respiratory vaccine to protect against RSV, COVID-19, and influenza. Insurers would be more likely to push that drug, as combining one shot for multiple protections is likely to increase compliance with recommended inoculations.</p><p><blockquote><h3><b>现在怎么办</b></h3>如果Moderna能够将该药物商业化，它就不必分享回报。它拥有该资产的100%。尽管该市场估计不到10亿美元，但影响可能会更大。它计划开发一种季节性呼吸道疫苗来预防呼吸道合胞病毒、新冠肺炎病毒和流感。保险公司更有可能推广这种药物，因为结合一次注射进行多种保护可能会提高对推荐接种的依从性。</blockquote></p><p> In the short term, the $19.2 billion Moderna expects from its COVID-19 vaccine far outweighs any impact from the RSV vaccine. However, it's a positive signal that the company will be able to leverage its mRNA platform andcommercialize drugsbeyond the pandemic.</p><p><blockquote>短期内，Moderna预计其COVID-19疫苗带来的192亿美元收入远远超过RSV疫苗的任何影响。然而，这是一个积极的信号，表明该公司将能够利用其mRNA平台并在大流行之外将药物商业化。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/03/why-shares-of-moderna-are-up-today/\">The Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/08/03/why-shares-of-moderna-are-up-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199496640","content_text":"A regulatory action is giving investors a glimpse of its business beyond the pandemic.\nWhat happened\nShares of Moderna, Inc. are up 9% as of 2:45 p.m. EDT today, after the Food and Drug Administration (FDA) granted Fast Track designation for mRNA-1345, the company's vaccine candidate for respiratory syncytial virus (RSV). In April, the company provided data showing an 11-fold and 20-fold increase in neutralizing antibodies for RSV-B and RSV-A, respectively, compared with its previous vaccine candidate.\nSo what\nRSV typically produces cold-like symptoms that last for a week or two. However, it does lead to about 58,000 hospitalizations in young children and 177,000 in older adults every year in the U.S. The agency's designation only applies to people over 60 years old.\nIMAGE SOURCE: GETTY IMAGES.\nThere is currently no approved vaccine for RSV. The Fast Track designation is a way for the FDA to expedite development of drugs that treat a currently unmet need. The process has lost some of its meaning in recent years. As an example, 73% of new drugs received the designation in 2018.\nNow what\nIf Moderna can commercialize the drug, it won't have to share the rewards. It owns 100% of the asset. Although the market is estimated at less than $1 billion, the impact could be more substantial. It plans to create a seasonal respiratory vaccine to protect against RSV, COVID-19, and influenza. Insurers would be more likely to push that drug, as combining one shot for multiple protections is likely to increase compliance with recommended inoculations.\nIn the short term, the $19.2 billion Moderna expects from its COVID-19 vaccine far outweighs any impact from the RSV vaccine. However, it's a positive signal that the company will be able to leverage its mRNA platform andcommercialize drugsbeyond the pandemic.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1936,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}